Nasdaq listed biopharmaceutical company in Foster City building antiviral, oncology and inflammation medicines
gilead.comLegal name
Gilead Sciences, Inc.
Founded
June 22, 1987 (founder Michael L. Riordan)
Headquarters
Foster City, California, United States
Industry
Biopharmaceuticals (virology, oncology, inflammation)
Employees
More than 17,000CEO
Daniel O'Day, Chairman and Chief Executive Officer
Revenue (FY25)
$29.44 billion
Market Cap
$161.83 billion (as of July 22, 2026)
Listed on
Nasdaq: GILD
Gilead Sciences, Inc. is a US biopharmaceutical company founded on June 22, 1987 by Michael L. Riordan and headquartered in Foster City, California. It trades on Nasdaq under the ticker GILD and is a component of the S&P 500 and Nasdaq-100. The company describes its mission as discovering, developing and delivering innovative therapeutics for people with life threatening diseases.
The business is built around three therapeutic areas: virology, oncology and inflammation. Gilead is best known for its HIV franchise, which includes Biktarvy and Descovy, and it has expanded into cell therapy through Kite and into antibody drug conjugates with Trodelvy. In June 2026 the FDA approved Trodelvy for first line treatment of metastatic triple negative breast cancer, and Gilead and Merck reported positive Phase 3 data in July 2026 for a once weekly oral HIV regimen combining lenacapavir and islatravir.
Gilead employs more than 17,000 people and operates in over 35 countries. Reported revenue was $29.44 billion for fiscal 2025, and market capitalization stood at about $161.8 billion in late July 2026. First quarter 2026 revenue reached $7.0 billion, up 4% year over year, with total HIV sales up 10% to $5.0 billion. The company has been actively acquiring, closing the $7.8 billion Arcellx deal in April 2026 and agreeing to buy German ADC developer Tubulis for $3.15 billion upfront.
Chairman and Chief Executive Officer
Chief Financial Officer
Chief Commercial & Corporate Affairs Officer
Chief Medical Officer
Interview experience
8/10 favorable
Interview difficulty
Medium, 6/10
Interview process length
About a week for most candidates
Practice real questions, get instant feedback and walk in ready for every round.
Q: What experience do you have with biologics?
A: Walk through the modalities you've handled and the assays you ran on them, then tie that to QC release or stability work. Keep it concrete: molecule type, your role, the method, and what the data was used for.
Q: Did you work with PMOs or CTLs before?
A: Say plainly whether you have, then describe the working relationship rather than just the acronym. If you haven't, describe the closest cross functional partner you've supported and how you handled their timelines.
Q: Do you have regulatory affairs experience?
A: Be honest about depth. Most QC scientists contribute to filings rather than own them, so describe what you actually supplied: method sections, validation data, deviation write ups or responses to agency questions.
Q: Do you give tours and presentations at your current job?
A: They're checking whether you can represent the lab to outsiders. Say who your audiences have been, how often, and how you adjust the level of detail for a non technical group.
Practice real questions, get instant feedback and walk in ready for every round.
Reported average
$87,583/yr
6 salaries reported Salaries submitted
Reported average
$109,476/yr
19 salaries reported Salaries submitted
Reported average
$133,035/yr
14 salaries reported Salaries submitted
Reported average
$154,246/yr
10 salaries reported Salaries submitted
Reported average
$158,592/yr
14 salaries reported Salaries submitted
Reported average
$190,520/yr
10 salaries reported Salaries submitted
Compare pay across roles and find the ones that match your experience.
San Francisco Bay Area, CA • Not specified
San Francisco Bay Area, CA • Not specified
San Francisco Bay Area, CA • Not specified
San Francisco Bay Area, CA • Not specified
San Francisco Bay Area, CA • Not specified
Pasadena, CA • Not specified
Tailor your resume to each Gilead Sciences role in minutes.
July 21, 2026
Gilead and Merck report Phase 3 wins for once weekly oral HIV pill
The investigational once weekly regimen combining Gilead's lenacapavir with Merck's islatravir met primary endpoints in the ISLEND-1 and ISLEND-2 switch studies at week 48. Data will be presented at AIDS 2026 and support planned regulatory submissions.
#HIV #ClinicalTrials #Pharma
View postJune 24, 2026
FDA approves Trodelvy for first line metastatic triple negative breast cancer
Trodelvy was cleared as a single agent for patients ineligible for PD-(L)1 therapy and in combination with Keytruda for PD-L1 positive tumors. Approval was based on the ASCENT-03 and ASCENT-04 Phase 3 trials.
#Oncology #FDAApproval #BreastCancer
View postMay 7, 2026
Gilead posts $7.0 billion in first quarter 2026 revenue
Total revenue rose 4% year over year, with HIV sales up 10% to $5.0 billion and Biktarvy at $3.4 billion. Full year product sales guidance was set at $30.0 billion to $30.4 billion.
#Earnings #Q12026 #HIV
View postApril 28, 2026
Gilead closes $7.8 billion acquisition of Arcellx
Gilead paid $115 per share in cash plus a $5 contingent value right, making Arcellx a wholly owned subsidiary. The deal gives Gilead full control of anito-cel, a BCMA directed CAR T therapy for multiple myeloma.
#MandA #CellTherapy #Oncology
View postApril 7, 2026
Gilead agrees to acquire German ADC developer Tubulis
The deal covers $3.15 billion upfront in cash plus up to $1.85 billion in milestone payments. Lead asset TUB-040 is a NaPi2b targeting antibody drug conjugate in Phase 1b/2 for ovarian cancer and non small cell lung cancer.
#MandA #ADC #Oncology
View postGilead is a US biopharmaceutical company that discovers, develops and delivers medicines across three therapeutic areas: virology, oncology and inflammation. It's best known for its HIV franchise, including Biktarvy and Descovy, and it also works in cell therapy through Kite and in antibody drug conjugates with Trodelvy.
